글로벌 안과 약물 시장 – 2031년까지의 산업 동향 및 예측

안과 약물 시장 분석 및 규모

안과 약물 시장은 최첨단 방법과 기술에 의해 주도되어 급속한 발전을 겪고 있습니다. 지속 방출 임플란트 및 나노 기술과 같은 혁신은 치료 효능과 환자 준수에 혁명을 일으키고 있습니다. 이러한 성장은 전 세계적으로 눈 질환이 증가하는 데 대응합니다. 세계보건기구의 2021년 10월 보고서는 시력 장애로 인해 영향을 받는 사람이 약 22억 명에 달한다고 강조했습니다. 이 통계는 증가하는 의료 수요를 효과적으로 충족하기 위해 지속적인 연구 개발이 시급히 필요하다는 것을 강조합니다. 시장의 궤적은 전 세계 수백만 명의 사람들에게 향상된 치료 결과와 향상된 삶의 질을 약속하는 혁신적인 솔루션으로의 중요한 전환을 강조합니다.                                

글로벌 안과 약물 시장 규모는 2023년에 3,037만 달러로 평가되었으며, 2031년까지 5,336만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 7.3%입니다. 이는 시장 가치를 나타냅니다. 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

시장 정의

안과 약물은 눈 질환을 치료하기 위해 고안된 약물입니다. 눈약, 연고 또는 젤과 같은 다양한 형태로 제공됩니다. 이러한 약물은 눈의 건조함, 가려움 또는 감염과 같은 증상을 완화하는 데 사용됩니다. 일부 안과 약물은 녹내장 이나 염증과 같은 질환을 관리하기 위해 처방되기도 합니다. 적절한 적용과 복용량 지침 준수는 효과를 위해 매우 중요합니다.            

안과 약물 시장 동향

운전자

• 눈 질환의 유병률 증가

녹내장, 백내장 , 당뇨망막병증 , 연령관련 황반변성과 같은 안구 질환의 유병률 증가는 안과 약물에 대한 수요를 크게 촉진하고 있습니다. 예를 들어, 전 세계 당뇨병 유행병으로 인해 당뇨망막병증 사례가 증가함에 따라 보다 진보된 치료법이 필요해지고 시장이 활성화되고 있습니다. 결과적으로 이러한 질환에 대한 환자 풀이 증가함에 따라 혁신적이고 효과적인 안과 치료법에 대한 시장 성장이 촉진되고 있습니다.

• 약물 전달의 기술적 발전

지속 방출 임플란트 및 나노입자 제형과 같은 약물 전달의 기술적 발전은 안과 약물의 효능과 환자 준수도를 크게 향상시킵니다. 예를 들어, 녹내장용 지속 방출 임플란트는 수개월 동안 일관된 약물을 제공하여 잦은 눈약의 필요성을 줄입니다. 이러한 혁신은 치료 결과와 편의성을 개선하여 환자의 요구를 보다 효과적으로 충족하고 치료 옵션을 확대함으로써 안과 약물 시장을 주도합니다.

기회

• 인식 확대 및 스크리닝 프로그램

Growing awareness about eye health and expanded screening programs have led to earlier diagnosis and treatment of eye conditions, significantly fueling the demand for ophthalmic drugs. For instance, initiatives such as World Glaucoma Week have increased public awareness, prompting more people to undergo regular eye check-ups. This proactive approach results in timely intervention, thereby driving the market for ophthalmic drugs as more individuals seek treatment for newly diagnosed conditions.

• Government Initiatives and Policies

Government initiatives and policies, such as subsidies and public health campaigns, are instrumental in reducing the burden of eye diseases, thereby driving market growth for ophthalmic drugs. For instance, the U.S. government's Healthy People 2030 initiative aims to improve eye health through preventive services and education, increasing the demand for treatments. Such supportive measures facilitate better access to ophthalmic care and stimulate the market's expansion. 

Restraints/Challenges

• Complex Manufacturing Processes

Complex manufacturing processes in the ophthalmic drugs market pose significant challenges. High precision is essential in drug formulation and production, demanding advanced technologies and skilled personnel. Additionally, stringent sterility and stability requirements must be met to ensure product safety and efficacy. These factors lead to increased production costs and time, further complicating the development and availability of ophthalmic drug. 

• High Development Costs

High development costs are a significant restraint in the ophthalmic drugs market. Expensive research and development investments and the high cost of clinical trials and regulatory compliance create substantial financial barriers. These costs hinder the market by limiting the ability of smaller companies to compete and slowing the introduction of new drugs. Consequently, innovation is stifled, and market growth is restricted due to these financial burdens.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2023, Bayer AG submitted aflibercept 8 mg for regulatory approval in the European Union, targeting two major retinal diseases. This submission is a significant step for Bayer, as aflibercept is expected to provide an advanced treatment option for patients suffering from these conditions, potentially improving visual outcomes and quality of life for many individuals across Europe
• In January 2023, Bausch Health Companies, Inc. launched PreserVision AREDS 2 Formula minigel eye vitamins in the United States. This product is specifically formulated for individuals with moderate-to-advanced Age-related Macular Degeneration (AMD). The mini gel format offers an easier-to-swallow alternative to traditional eye vitamins, aiming to enhance patient compliance and support eye health effectively
• In April 2022, Sandoz, a Novartis company, introduced its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5% in the United States. This product is an AB-rated generic equivalent to AbbVie's COMBIGAN and is designed to lower intraocular pressure in patients with ocular hypertension. The launch provides a more affordable treatment option while maintaining efficacy and safety standards
• In March 2022, Théa Pharma acquired seven branded ophthalmic products from Akorn Operating Company LLC. This strategic acquisition enhances Théa Pharma's portfolio and strengthens its position in the U.S. market. The newly acquired products are expected to meet the diverse needs of eye care specialists, allowing Théa Pharma to offer comprehensive solutions for various ophthalmic conditions

Ophthalmic Drugs Market Scope

The market is segmented on the basis of drugs, disease, dosage form, route of administration, product type, product, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Anti-Inflammatory
  • NSAID’s
  • Steroied
• Anti-Infective
  • Anti-Fungal
  • Anti-Bacterial
  • Others
•  Anti-Glaucoma
  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Combined Medication
  • Others
•  Anti-Allergy
•  Anti-Vascular Endothelial Growth Factor
•  Others

 Disease

• Dry Eye
• Allergies
• Glaucoma
• Eye Infection
• Infection
• Retinal Disorders
• Uveitis
  • Gels
  • Eye Solutions and Suspensions
  • Capsules and Tablets
  • Eye Drops
  • Ointments
• Others

 Dosage Form

• Gels
• Eye Solutions and Suspensions
• Capsules and Tablets
• Eye Drops
• Ointments

 Route of Administration

• Topical
  • Retinal Disorders
  • Subconjunctival
  • Intravitreal
  • Retrobulbar
  • Intracameral
• Local Ocular
• Systemic

 Product Type

• Prescription Drugs
• OTC

 Product

• Branded Drugs
• Generic Drugs

 End-Users

• Hospitals
• Specialty Clinics
• Others

 Distribution Channel

• Direct
• Indirect

Ophthalmic Drugs Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, drugs, disease, dosage form, route of administration, product type, product, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth in the ophthalmic drugs market due to the increased prevalence of eye diseases and rising awareness. Research and development by major players such as Alcon, Pfizer Inc., and Bausch and Lomb, along with frequent product launches, further boost regional growth.

Asia-Pacific is expected to dominate the ophthalmic drugs market due to its large patient base, high disease incidence, and the rise of local companies. Strategic initiatives by major players further bolster regional growth prospects in this vital healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Ophthalmic Drugs Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Akorn Operating Company LLC. (U.S.)
• Johnson & Johnson Services, Inc.(U.S.)
• Mitotech Ltd  (Germany)
• AbbVie Inc. (U.S.)
• 산텐제약 주식회사(일본).
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Bausch Health Companies Inc. (캐나다)
• AERIE PHARMACEUTICALS, INC. (미국)
• 노바티스 AG(스위스)
• 머크앤코(미국)
• Bayer AG(독일)
• F. 호프만-라 로슈 유한회사(스위스)

SKU-52898